Disciplined Growth Investors Inc. MN cut its holdings in shares of MiMedx Group, Inc (NASDAQ:MDXG) by 0.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 726,225 shares of the medical equipment provider’s stock after selling 1,000 shares during the period. Disciplined Growth Investors Inc. MN owned approximately 0.65% of MiMedx Group worth $10,872,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Kestrel Investment Management Corp bought a new position in MiMedx Group during the second quarter worth about $10,210,000. State of Wisconsin Investment Board bought a new stake in shares of MiMedx Group in the second quarter valued at about $1,183,000. Paradigm Asset Management Co. LLC bought a new stake in shares of MiMedx Group in the second quarter valued at about $167,000. OppenheimerFunds Inc. lifted its holdings in shares of MiMedx Group by 45.2% in the first quarter. OppenheimerFunds Inc. now owns 22,860 shares of the medical equipment provider’s stock valued at $217,000 after purchasing an additional 7,112 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of MiMedx Group in the second quarter valued at about $504,000. Hedge funds and other institutional investors own 60.37% of the company’s stock.

MiMedx Group, Inc (NASDAQ:MDXG) traded down 0.08% during mid-day trading on Friday, hitting $13.20. The company had a trading volume of 3,659,360 shares. MiMedx Group, Inc has a 12-month low of $7.64 and a 12-month high of $17.47. The company’s 50 day moving average price is $13.62 and its 200-day moving average price is $13.84. The firm has a market capitalization of $1.42 billion, a PE ratio of 69.47 and a beta of 0.91.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, July 26th. The medical equipment provider reported $0.07 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.07. MiMedx Group had a net margin of 7.48% and a return on equity of 15.95%. The firm had revenue of $76.40 million during the quarter, compared to analyst estimates of $74.22 million. During the same quarter last year, the business posted $0.05 EPS. The company’s revenue for the quarter was up 33.3% on a year-over-year basis. On average, analysts forecast that MiMedx Group, Inc will post $0.31 EPS for the current fiscal year.

MiMedx Group announced that its Board of Directors has initiated a stock buyback program on Wednesday, July 26th that authorizes the company to buyback $14.00 million in shares. This buyback authorization authorizes the medical equipment provider to buy up to 0.9% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

MDXG has been the topic of a number of research reports. Piper Jaffray Companies restated a “buy” rating and issued a $18.00 price target on shares of MiMedx Group in a report on Sunday, August 20th. Needham & Company LLC boosted their price target on MiMedx Group from $20.00 to $21.00 and gave the company a “strong-buy” rating in a report on Tuesday, September 5th. Zacks Investment Research lowered MiMedx Group from a “hold” rating to a “sell” rating in a report on Tuesday. Lake Street Capital boosted their price target on MiMedx Group from $16.00 to $18.00 and gave the company a “buy” rating in a report on Friday, July 28th. Finally, BidaskClub upgraded MiMedx Group from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Three analysts have rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. MiMedx Group currently has a consensus rating of “Hold” and an average target price of $14.83.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.watchlistnews.com/mimedx-group-inc-mdxg-holdings-trimmed-by-disciplined-growth-investors-inc-mn/1630649.html.

MiMedx Group Company Profile

MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.

Institutional Ownership by Quarter for MiMedx Group (NASDAQ:MDXG)

Receive News & Ratings for MiMedx Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.